# TIDE-A (NCT04698213)

> Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04698213
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Consorzio Oncotech
- Conditions: Renal Carcinoma Metastatic
- Interventions: Axitinib Oral Tablet; Avelumab
- Enrollment: 75
- Primary outcome: Overall response rate (ORR)

## Commentary we found

- X threads: 10
- Podcasts: 3
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tide-a-nct04698213

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04698213", "email": "<work email>"}; the inbox owner confirms by the emailed link.